Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis in Japan

This article was originally published in The Tan Sheet

Executive Summary

Consumer Health division forms joint venture with household products company Kao to introduce OTC brands in Japan. The Novartis Kao portfolio will include new products developed for the Japanese market, international brands suitable for Japan and pharmaceuticals appropriate for switching from Rx status. In January 2001, the Tokyo-based firm will launch an eyecare product for the relief of eyestrain symptoms. Other products will target fatigue, muscle aches and back pain. McNeil Consumer Healthcare recently announced a partnership with Takeda Chemical Industries to launch Tylenol analgesics in Japan (1"The Tan Sheet" July 24, p. 19)

Consumer Health division forms joint venture with household products company Kao to introduce OTC brands in Japan. The Novartis Kao portfolio will include new products developed for the Japanese market, international brands suitable for Japan and pharmaceuticals appropriate for switching from Rx status. In January 2001, the Tokyo-based firm will launch an eyecare product for the relief of eyestrain symptoms. Other products will target fatigue, muscle aches and back pain. McNeil Consumer Healthcare recently announced a partnership with Takeda Chemical Industries to launch Tylenol analgesics in Japan (1 (Also see "McNeil Partnership With Takeda Leads To Tylenol Japan Launch" - Pink Sheet, 24 Jul, 2000.)).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel